Chicago, IL – Hill-Rom Holdings, Inc. has announced the introduction of the VisiVest System, a connected therapeutic solution for patients in need of airway clearance therapy. The world’s first solution combining industry-leading high-frequency chest-wall oscillation (HFCWO) technology with wireless connectivity powered by Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated, the VisiVest System provides therapy adherence data that may help inform decisions caregivers make for their patients, resulting in reduced risk of respiratory infections, hospitalizations and medical costs.
Patients’ usage data from the VisiVest System is remotely and securely transmitted to the VisiView Health Portal via Qualcomm Life’s 2net Hub enabling highly secure, medical-grade connectivity and effortless user experience. The VisiView Health Portal, developed by Razorfish, an application development company, then displays data trends in an easy-to-use dashboard format. This connectivity fosters a closer partnership between patients and health care teams, so treatment decisions by caregivers can be more tailored and responsive, which may result in better therapy adherence.
“In healthcare, the ability to make decisions based on accurate, timely information is essential,” said Alton Shader, president, Front Line Care at Hill-Rom. “The VisiVest System and Qualcomm Life’s 2net connectivity solution bring care teams and patients closer, helping to better manage patients’ illness and improve their quality of life.”
“We are thrilled to be working with a global industry leader in health care technology and excited by the impact our collaboration with Hill-Rom can have for chronic lung disease patients and their caregivers,” said Rick Valencia, president, Qualcomm Life, Inc. “By combining Hill-Rom’s leadership in health care with Qualcomm Life’s expertise in connectivity, we are innovating to deliver effortless connected experiences that empower patients and their care providers.”
In a pilot study conducted over the past few months, 160 patients from seven cystic fibrosis clinics have adopted The VisiVest System. Patients and care teams have responded with great enthusiasm and excitement for the technology.
“What I like most about the VisiVest System is being able to see my patients’ session data and trends,” said Tom Newton, pulmonary therapist, Miller Children’s Hospital, Long Beach, California. “Now I’m not just telling my patients the more adherent they are to their therapy, the higher their pulmonary function numbers are likely to be. We can actually look at their adherence score together and have a more comprehensive conversation about their numbers.”
Connected health solutions will continue to strengthen Hill-Rom’s leadership role in the respiratory care industry.
For more information, visit hill-rom.com.